Kezar Life Sciences, Inc. (KZR) Form 8-K — May 11, 2026
$KZRForm 8-KItems 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01Filed May 11, 2026, 9:30 AM ET0001140361-26-020407Original filing
Kezar Life Sciences, Inc. has completed its acquisition by Aurinia Pharma U.S., Inc. following a successful tender offer where approximately 80.2% of outstanding shares were tendered at a price of $6.955 per share in cash plus one contingent value right (CVR) per share. The merger was finalized on May 11, 2026, without a stockholder vote, and the company will now operate as a wholly owned subsidiary of Aurinia.
Key figures
- Offering Price
- $6.955
- Shares Tendered
- 5927580
- Cvr
- 1 per share
- Percent tendered
- 80.2%
Price after filing
1 day: 0.0%7 days: 0.0%
Close on the filing date to close N calendar days later (from $7.29). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.